Chugai files for Elevidys approval in Japan for DMD
Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for gene therapy delandistrogene moxeparvovec, for the treatment of Duchenne muscular dystrophy (DMD).
Trade-marked Elevidys overseas, the drug’s target population aims to include ambulatory boys aged three-seven years with DMD who do not have any deletion in exons 8 and/or 9 in the DMD gene and do not have a pre-existing immunity against AAVrh74, said Chugai, which licensed the drug from its majority owner Swiss pharma giant Roche (ROG: SIX) in 2021.
Marketresearch.biz has previously reported that the Duchenne muscular dystrophy market was valued at $3.5 billion in 2023. It is expected to reach $11.7 billion in 2033, with a compound annual growth rate (CAGR) of 13.16% during the forecast period from 2024 to 2033.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze